Metered‐dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A cost‐effectiveness analysis in a middle‐income country

Vista sencilla de ítem
dc.contributor.authorRodriguez-Martinez, Carlos E.
dc.contributor.authorSossa-Briceño, Monica P.
dc.contributor.authorCastro-Rodriguez, Jose A.
dc.date.accessioned2020-02-14T18:48:38Z
dc.date.available2020-02-14T18:48:38Z
dc.date.issued2020
dc.description.abstractenglishObjectives Although the benefits of albuterol delivered via metered‐dose inhalers with a spacer (MDI+S) have been increasingly recognized, the evidence regarding the cost‐effectiveness of MDI+S compared to nebulization (NEB) is not sufficient, especially in less‐affluent countries, where the clinical and economic burden of the disease is the greatest. The aim of the present study was to evaluate the cost‐effectiveness of MDI+S vs NEB for delivering albuterol for the treatment of pediatric asthma exacerbations. Methods A decision‐analysis model was developed to estimate the cost‐effectiveness of MDI+S vs NEB for delivering albuterol for the treatment of pediatric asthma exacerbations. Effectiveness parameters were obtained from a systematic review of the literature. Cost data were obtained from hospital bills and from the national manual of drug prices in Colombia. The study was carried out from the perspective of the national healthcare system in Colombia, a middle‐income country (MIC). The main outcome of the model was the avoidance of hospital admission. Results For the base‐case analysis, the model showed that compared to NEB, using MDI+S for the delivery of albuterol was associated with lower total costs (US$96.68 vs US$121.41 average cost per patient) and a higher probability of hospital admission avoided (0.9219 vs 0.8900), thus leading to dominance. Conclusions This study shows that in Colombia, an MIC, compared with NEB, the use of MDI+S for delivering albuterol for the treatment of pediatric asthma exacerbations is the preferred strategy because it is associated with a lower probability of hospital admission at lower total treatment costs.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1002/ppul.24650
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1099-0496
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/1939
dc.language.isoeng
dc.publisherWileyspa
dc.publisher.journalPediatric Pulmonologyspa
dc.relation.ispartofseriesPediatric Pulmonology, 1099-0496, 2020.spa
dc.relation.urihttps://onlinelibrary.wiley.com/doi/abs/10.1002/ppul.24650
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf295
dc.rights.creativecommons2020
dc.rights.localAcceso cerradospa
dc.subject.decsInhaladores de dosis medidaspa
dc.subject.decsAnálisis costo-beneficiospa
dc.subject.decsNebulizadores y vaporizadoresspa
dc.titleMetered‐dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A cost‐effectiveness analysis in a middle‐income countryspa
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartículospa

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos